ArticleJournal of clinical laboratory analysis2025
Phenotypic, Targeted Genotypic, and Antimicrobial Susceptibility Profiling of Extended-Spectrum β-Lactamase Production and Exclusive bla
Article in Journal of clinical laboratory analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, multidrug resistance (MDR), including extended-spectrum β-lactamase (ESBL) and carbapenemase production in Enterobacteriaceae, is increasing. Data concerning their presence in South Lebanon are scarce. This study aimed to determine the prevalence of ESBL and carbapenem-resistant Enterobacteriaceae (CRE) in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates from the Saida region.
methodsIn Hammoud Hospital University Medical Center (HHUMC), and over a period of 9 months, identification and susceptibility testing of the isolates using the Kirby-Bauer method were performed and then confirmed as recommended by the Clinical and Laboratory Standards Institute (CLSI). Molecular analysis of the genes encoding ESBL and carbapenemases was investigated by polymerase chain reaction (PCR).
resultsA total of 200 isolates (171 E. coli and 29 K. pneumoniae) were obtained from different clinical specimens (urine, rectal swabs, blood, sputum, pus, wound/tissue, nasal swabs, vaginal swabs) and were subsequently studied. Nearly 89.5% (179/200) and 10.5% (21/200) of the isolates were producers of ESBL and carbapenemase, respectively. The ESBL isolates showed high sensitivity toward carbapenem drugs, whereas the CRE isolates were most sensitive to tigecycline. Of 67 studied ESBL isolates, bla
conclusionThis type of scenario highlights the necessity of using antibiotics sparingly and putting stringent measures in place to prevent infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.